3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Thoracic
2
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Conditions
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
Temozolomide
33
Radiotherapy
32
pembrolizumab
18
Cyclophosphamide
18
Irinotecan
16
Gemcitabine
16
Doxorubicin
16
Nivolumab
11
Docetaxel
11
Sirolimus
10
Imatinib Mesylate
10
Ifosfamide
10
Filgrastim
10
Radiation
9
Bevacizumab
9
Vincristine
8
Carboplatin
8
pazopanib
7
Everolimus
7
temsirolimus
6
atezolizumab
6
Peripheral Blood Stem Cell Transplantation
6
Etoposide
6
fludarabine phosphate
5
Vorinostat
5
Specimen Handling
5
Radiotherapy, Conformal
5
PM 01183
5
Ipilimumab
5
Erlotinib Hydrochloride
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Immunotherapy
×
Sarcoma
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled